Evidence map›Paper›PMID 30816632›Full record

Trial reportJournal of the International AIDS Society2019

Acquisition of Sexually Transmitted Infections among Women Using a Variety of Contraceptive Options: A prospective Study among High-risk African Women.

Flavia Matovu Kiweewa, Elizabeth Brown, Anu Mishra, Gonasagrie Nair, Thesla Palanee-Phillips, Nyaradzo Mgodi, Clemensia Nakabiito, Nahida Chakhtoura, Sharon L Hillier, Jared M Baeten and 1 more

Erratum issuedOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of the International AIDS Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Sexually Transmitted Infections Treatment Guidelines, 2021.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2021
    Guideline
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Contraceptive effects on the cervicovaginal microbiome: Recent evidence including randomized trials.American journal of reproductive immunology (New York, N.Y. : 1989) · 2023
    Review
  7. Article
  8. Article
  9. Article
  10. Multiattribute Analysis ofInfectious diseases in obstetrics and gynecology · 2021
    Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 6 countries.

Flavia Matovu KiweewaMakerere University - Johns Hopkins University Research Collaboration, Kampala, Uganda.ORCID 0000-0002-0046-4353
Elizabeth BrownFred Hutchinson Cancer Research Center, Seattle, WA, USA.
Anu MishraUniversity of Washington, Seattle, WA, USA.
Gonasagrie NairEmavundleni Research Centre, CapeTown, Republic of South Africa.
Thesla Palanee-PhillipsWits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, Republic of South Africa.
Nyaradzo MgodiUniversity of Zimbabwe College of Health Sciences Clinical Trials Research Centre, Harare, Zimbabwe.
Clemensia NakabiitoMakerere University - Johns Hopkins University Research Collaboration, Kampala, Uganda.
Nahida ChakhtouraNational Institute of Child Health and Human Development/National Institute of Health, Bethesda, MD, USA.
Sharon L HillierUniversity of Pittsburgh, Pittsburgh, PA, USA.
Jared M BaetenUniversity of Washington, Seattle, WA, USA.ORCID 0000-0001-8242-8438
MTN-020/ASPIRE Study Team
University of Washington · USMUJHU Research Collaboration · UGAfrican Organisation for Research and Training in Cancer · ZANational Institute of Child Health · HUUniversity of Pittsburgh · USUniversity of the Witwatersrand · ZAUniversity of Zimbabwe · ZW

Funding

Microbicide Trials NetworkUM1AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2011 to 2021
$175.0M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI EDWIN ROBERTO ORELLANA · 1988 to 2026
$104.9M
UZ-UCSF CTUUM1AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZVAVAHERA MIKE CHIRENJE, LYNDA STRANIX-CHIBANDA · 2012 to 2026
$75.9M
Statistical and Data Management Center (SDMC): Microbicide Trials NetworkUM1AI068615 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BROWN, ELIZABETH RENATA · 2011 to 2021
$66.5M
UZ-UCSF Clinical Trials UnitU01AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIRENJE, ZVAVAHERA MIKE · 2007 to 2011
$49.3M
The Malawi Clinical Trials UnitUM1AI069518 · NIAID · JOHNS HOPKINS UNIVERSITY · PI JACKY M JENNINGS, TAHA E TAHA · 2012 to 2026
$43.8M
The Johns Hopkins University - Uganda Clinical Trials UnitUM1AI069530 · NIAID · JOHNS HOPKINS UNIVERSITY · PI MARY Glenn Fowler, Philippa Musoke · 2012 to 2026
$34.8M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
Laboratory Center (LC): Microbicide Trials NetworkUM1AI106707 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI MELLORS, JOHN W, ROHAN, LISA CENCIA · 2014 to 2021
$27.1M
Units for HIV/AIDS Clinical Trials NetworksU01AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI SANNE, IAN MATTHIAS · 2007 to 2011
$24.2M
BIOMEDICAL INFORMATION DEVELOPMENT IN SUB-SAHARAN AFRICAD43TW001081 · FIC · JOHNS HOPKINS UNIVERSITY · PI TAHA, TAHA E · 1998 to 2003
$435k
FIC NIH HHS D43 TW001081NIAID NIH HHS P30 AI027757NIAID NIH HHS U01 AI069436NIAID NIH HHS U01 AI069463NIAID NIH HHS UM1 AI068615NIAID NIH HHS UM1 AI068633NIAID NIH HHS UM1 AI069436NIAID NIH HHS UM1 AI069463NIAID NIH HHS UM1 AI069518NIAID NIH HHS UM1 AI069530NIAID NIH HHS UM1 AI106707
6 · The paper itself

Abstract

introductionIn many African settings, women concurrently face substantial risk of human immunodeficiency virus type 1 (HIV-1) infection, sexually transmitted infections (STIs) and unintended pregnancies. Few studies have evaluated STI risk among users of hormonal implants and copper intrauterine devices (IUDs) although these long-acting reversible contraceptive methods are being promoted widely because of their benefits. Within a prospective study of women at risk for HIV-1, we compared the risk of acquisition of Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis among women using different contraceptive methods.

methodsMTN-020/ASPIRE was a randomized trial of the dapivirine vaginal ring for HIV-1 prevention among 2629 women aged 18 to 45 years from Malawi, South Africa, Uganda and Zimbabwe, of whom 2264 used copper IUDs or progestin-based injectables or implants during follow-up. Screening for the above STIs occurred semi-annually.

resultsOver 3440 person-years of follow-up, 408 cases of C. trachomatis (incidence 11.86/100 person-years), 196 of N. gonorrhoeae (5.70/100 person-years) and 213 cases of T. vaginalis (6.19/100 person-years) were detected. C. trachomatis and N. gonorrhoeae incidence were not significantly different across contraceptive methods. T. vaginalis incidence was significantly higher for copper IUD users compared to depot medroxyprogesterone acetate (DMPA), implant and norethisterone enanthate users.

conclusionAmong African women at high HIV-1 risk, STIs were common. Risk of cervical infections did not differ across contraceptive methods. Significantly higher rates of T. vaginalis were observed among progestin-based methods compared to copper IUD users. Overall, these findings call for more intensive routine screening for STIs, and they support current World Health Organization guidance that women should have a wide range of contraceptive options.

Indexed as

ContraceptionAdolescentAdultContraceptive Devices, FemaleFemaleHIV InfectionsHumansIncidenceMalawiMiddle AgedPregnancyProspective StudiesSexually Transmitted DiseasesSouth AfricaUgandaWomenchlamydiagonorrhoeahormonal contraceptionsexually transmitted diseasestrichomoniasis

Identifiers

PMID30816632
PMCPMC6393855
OpenAlexW2920025628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.